Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
Background: About a third of patients with inflammatory bowel disease do not respond to anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the current data on the two main strategies when facing primary non-response to an anti-TNF agent in inflammatory bowel disease...
Saved in:
Main Authors: | Javier P. Gisbert, María Chaparro |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/ae22f2dd12284d1cb595702d40cc02e2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
by: Byron P. Vaughn
Published: (2021) -
Attributes of intestinal microbiota composition and their correlation with clinical primary nonresponse to anti-TNF-α agents in inflammatory bowel disease patients
by: Hanan Alatawi, et al.
Published: (2021) -
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
by: D'Angelo S, et al.
Published: (2017) -
Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
by: Rawla P, et al.
Published: (2018) -
Experiencia local con natalizumab en pacientes con enfermedad de Crohn refractaria a anti-TNF: Casos clínicos
by: Fluxá,Daniela, et al.
Published: (2017)